WO2007038571A3 - Prolyl hydroxylase antagonists - Google Patents

Prolyl hydroxylase antagonists Download PDF

Info

Publication number
WO2007038571A3
WO2007038571A3 PCT/US2006/037611 US2006037611W WO2007038571A3 WO 2007038571 A3 WO2007038571 A3 WO 2007038571A3 US 2006037611 W US2006037611 W US 2006037611W WO 2007038571 A3 WO2007038571 A3 WO 2007038571A3
Authority
WO
WIPO (PCT)
Prior art keywords
antagonists
prolyl hydroxylase
quinolin
carbonyl
useful
Prior art date
Application number
PCT/US2006/037611
Other languages
French (fr)
Other versions
WO2007038571A2 (en
Inventor
Deping Chai
Mariela Colon
Kevin J Duffy
Duke M Fitch
Rosanna Tedesco
Michael N Zimmerman
Original Assignee
Smithkline Beecham Corp
Deping Chai
Mariela Colon
Kevin J Duffy
Duke M Fitch
Rosanna Tedesco
Michael N Zimmerman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Deping Chai, Mariela Colon, Kevin J Duffy, Duke M Fitch, Rosanna Tedesco, Michael N Zimmerman filed Critical Smithkline Beecham Corp
Publication of WO2007038571A2 publication Critical patent/WO2007038571A2/en
Publication of WO2007038571A3 publication Critical patent/WO2007038571A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Abstract

This invention relates to certain 2-[(quinolin-3-yl)carbonyl]aminoacetic acid derivatives of formula (I), where the various groups are defined herein, and which are useful in treating anemia.
PCT/US2006/037611 2005-09-26 2006-09-26 Prolyl hydroxylase antagonists WO2007038571A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72052005P 2005-09-26 2005-09-26
US60/720,520 2005-09-26

Publications (2)

Publication Number Publication Date
WO2007038571A2 WO2007038571A2 (en) 2007-04-05
WO2007038571A3 true WO2007038571A3 (en) 2007-10-11

Family

ID=37900404

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/037611 WO2007038571A2 (en) 2005-09-26 2006-09-26 Prolyl hydroxylase antagonists

Country Status (1)

Country Link
WO (1) WO2007038571A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8927591B2 (en) 2008-11-14 2015-01-06 Fibrogen, Inc. Thiochromene derivatives as HIF hydroxylase inhibitors

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007070359A2 (en) * 2005-12-09 2007-06-21 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
LT3357911T (en) 2006-06-26 2022-08-10 Akebia Therapeutics Inc. Prolyl hydroxylase inhibitors and methods of use
WO2008062859A1 (en) 2006-11-22 2008-05-29 Ajinomoto Co., Inc. Process for production of phenylalanine derivatives having quinazolinedione skeletons and intermediates for the production
AU2007334321B2 (en) 2006-12-18 2012-03-08 Amgen Inc. Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
AU2007334323B2 (en) 2006-12-18 2011-03-10 Amgen Inc. Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
WO2008130527A1 (en) * 2007-04-18 2008-10-30 Merck & Co., Inc. Novel 1,8-naphthyridine compounds
ES2442847T3 (en) * 2007-04-18 2014-02-13 Amgen, Inc Quinolones and azaquinolones that inhibit prolyl hydroxylase
US7569726B2 (en) 2007-04-18 2009-08-04 Amgen Inc. Indanone derivatives that inhibit prolyl hydroxylase
EP2150251B9 (en) 2007-05-04 2013-02-27 Amgen, Inc Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
EP2155746A2 (en) * 2007-05-04 2010-02-24 Amgen, Inc Diazaquinolones that inhibit prolyl hydroxylase activity
US20100222347A1 (en) 2007-09-27 2010-09-02 Kowa Company, Ltd. Prophylactic and/or therapeutic agent for anemia, comprising tetrahydroquinoline compound as active ingredient
WO2009073669A1 (en) 2007-12-03 2009-06-11 Fibrogen, Inc. Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
WO2009086044A1 (en) * 2007-12-19 2009-07-09 Smith Kline Beecham Corporation Prolyl hydroxylase inhibitors
EP2252619B1 (en) 2008-01-11 2013-10-09 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
WO2009100250A1 (en) * 2008-02-05 2009-08-13 Fibrogen, Inc. Chromene derivatives and use thereof as hif hydroxylase activity inhibitors
EP2257170B1 (en) * 2008-02-25 2012-12-26 Merck Sharp & Dohme Corp. Tetrahydrofuropyridones
WO2009134754A1 (en) 2008-04-28 2009-11-05 Janssen Pharmaceutica Nv Benzoimidazole glycinamides as prolyl hydroxylase inhibitors
CN102264740B (en) 2008-08-20 2014-10-15 菲布罗根有限公司 Pyrrolo [ 1, 2 -b] pyridazine derivatives and their use as hif modulators
EP2326178A4 (en) * 2008-08-21 2012-10-24 Glaxosmithkline Llc Prolyl hydroxylase inhibitors
US8791090B2 (en) 2009-03-31 2014-07-29 Kowa Company, Ltd. Prophylactic and/or therapeutic agent for anemia comprising tetrahydroquinoline compound as active ingredient
US8815865B2 (en) 2009-06-30 2014-08-26 Merck Sharp & Dohme Corp. Substituted 4-hydroxypyrimidine-5-carboxamides
US8372857B2 (en) 2009-06-30 2013-02-12 Merck Sharp & Dohme Corp. Substituted 4-hydroxypyrimidine-5-carboxamides
ES2702524T3 (en) * 2009-07-15 2019-03-01 Beijing Betta Pharmaceuticals Co Ltd Compounds such as hypoxia mimetics, and compositions, and uses of these
TW201124397A (en) 2009-10-21 2011-07-16 Daiichi Sankyo Co Ltd 5-hydroxypyrimidine-4-carboxamide derivatives having a hydrocarbon ring group
AU2010314976B2 (en) 2009-11-06 2014-03-06 Aerpio Therapeutics Inc. Prolyl hydroxylase inhibitors
CA2813711A1 (en) 2010-10-14 2012-04-19 Immunahr Ab 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as ahr activators.
CN103608346B (en) 2011-02-02 2016-06-15 菲布罗根有限公司 As the 7-naphthyridine derivatives of hypoxia inducible factor (HIF) hydroxylase inhibitors
GB201102659D0 (en) 2011-02-15 2011-03-30 Isis Innovation Assay
NO2686520T3 (en) 2011-06-06 2018-03-17
AU2012268400C1 (en) 2011-06-06 2016-12-22 Akebia Therapeutics Inc. Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
GB201113101D0 (en) 2011-07-28 2011-09-14 Isis Innovation Assay
WO2013043624A1 (en) 2011-09-23 2013-03-28 Merck Sharp & Dohme Corp. Substituted pyrimidines
US9034851B2 (en) 2011-09-23 2015-05-19 Merck Sharp & Dohme Corp. Substituted pyrimidines
BR112014009910B1 (en) 2011-10-25 2020-06-30 Janssen Pharmaceutica N.V. 1- (5,6-dichloro-1h-benzo [d] imidazol-2-yl) -1h-pyrazol-4-carboxylic acid meglumine salt, pharmaceutical composition and topical ointment
RU2641291C2 (en) 2012-07-30 2018-01-17 Тайсо Фармасьютикал Ко., Лтд. Partly saturated nitrogen-containing heterocyclic compound
CN102964301A (en) * 2012-11-26 2013-03-13 盛世泰科生物医药技术(苏州)有限公司 Method for synthesizing IOX2
US9394300B2 (en) * 2012-12-24 2016-07-19 Cadila Healthcare Limited Quinolone derivatives
CA3151685A1 (en) 2013-06-13 2014-12-18 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
KR102495018B1 (en) 2013-11-15 2023-02-06 아케비아 테라퓨틱스 인코포레이티드 Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
ES2898476T3 (en) * 2014-09-02 2022-03-07 Sunshine Lake Pharma Co Ltd Quinolone compound and use thereof
WO2016045127A1 (en) * 2014-09-28 2016-03-31 Merck Sharp & Dohme Corp. Inhibitors of hif prolyl hydroxylase
WO2016045125A1 (en) * 2014-09-28 2016-03-31 Merck Sharp & Dohme Corp. Inhibitors of hif prolyl hydroxylase
AU2015374118B2 (en) 2014-12-29 2020-07-23 The Trustees Of The University Of Pennsylvania Small molecule inhibitors of lactate dehydrogenase and methods of use thereof
WO2016118858A1 (en) 2015-01-23 2016-07-28 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
SI3277270T1 (en) 2015-04-01 2022-04-29 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
CN105294648B (en) * 2015-11-30 2017-11-28 山东罗欣药业集团股份有限公司 A kind of preparation method of sitafloxacin
CN108069952B (en) * 2016-11-08 2022-09-27 广东东阳光药业有限公司 Quinolinone compound and application thereof in medicines
CA3097219A1 (en) 2018-05-09 2019-11-14 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
CN111269177B (en) * 2019-11-28 2023-05-09 广东东阳光药业有限公司 Crystal forms of quinolinone compounds
AU2020390281A1 (en) * 2019-11-28 2022-05-19 Sunshine Lake Pharma Co., Ltd. Crystal form of quinolinone compound and use thereof
CN115010664A (en) * 2021-03-05 2022-09-06 广东东阳光药业有限公司 Crystal form of quinolinone compound and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4738971A (en) * 1981-03-03 1988-04-19 Aktiebolaset Leo N-aryl-1,2-dihydro-4-substituted-1-alkyl-2-oxo-quinoline-3-carboxamides
US20030153503A1 (en) * 2001-12-06 2003-08-14 Klaus Stephen J. Methods of increasing endogenous erythropoietin (EPO)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4738971A (en) * 1981-03-03 1988-04-19 Aktiebolaset Leo N-aryl-1,2-dihydro-4-substituted-1-alkyl-2-oxo-quinoline-3-carboxamides
US20030153503A1 (en) * 2001-12-06 2003-08-14 Klaus Stephen J. Methods of increasing endogenous erythropoietin (EPO)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8927591B2 (en) 2008-11-14 2015-01-06 Fibrogen, Inc. Thiochromene derivatives as HIF hydroxylase inhibitors
US9149476B2 (en) 2008-11-14 2015-10-06 Fibrogen, Inc. Thiochromene derivatives as HIF hydroxylase inhibitors

Also Published As

Publication number Publication date
WO2007038571A2 (en) 2007-04-05

Similar Documents

Publication Publication Date Title
WO2007038571A3 (en) Prolyl hydroxylase antagonists
WO2005110994A3 (en) Substituted pyrazolyl urea derivatives useful in the treatment of cancer
WO2007021937A3 (en) Unsaturated heterocyclic derivatives
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
WO2009006389A8 (en) Pyrimidine derivatives useful as raf kinase inhibitors
WO2006091457A3 (en) Ionic liquids derived from peracid anions
WO2009077471A3 (en) Azolylmethyloxiranes, use thereof and agents containing the same
WO2007150011A8 (en) Prolyl hydroxylase inhibitors
WO2006113919A3 (en) Aryl alkyl acid derivatives for and use thereof
WO2006072612A3 (en) Triazolophthalazines as pde2- inhibitors
WO2007052023A3 (en) Novel compounds
WO2007136592A3 (en) 2-0x0-l,2-dihydr0quin0line derivatives, compositions, and uses thereof as antiproliferative agents
WO2009087098A3 (en) Quinoline derivatives and their use as fungicides
WO2006100082A3 (en) Substituted oxindol derivatives, drugs containing said derivatives and the use thereof
WO2008017346A3 (en) Ascorbic acid derivatives, use thereof for the functionalization of matrices
WO2007016674A3 (en) 2-aminoaryl pyridines as protein kinases inhibitors
WO2005079396A3 (en) O,o'-amidomalonate and n,o-amidomalonate platinum complexes
WO2007109279A3 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
WO2008076427A3 (en) Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
WO2008009831A3 (en) Novel amphiphilic cyclodextrin derivatives
WO2007074491A8 (en) HETEROTRICYCLIC AMIDE DERIVATIVES AS NEUROKININ-l (NKl) RECEPTOR LIGANDS
WO2007053597A3 (en) An anticorrosive paper or paperboard material
WO2009046842A3 (en) Thiazol derivatives for treating cancer
WO2006097617A3 (en) Novel dihydropyrimidine derivatives and their use as anti-cancer agents
WO2007038616A3 (en) Encapsulated emulsions and methods of preparation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06804190

Country of ref document: EP

Kind code of ref document: A2